Complaint Management Software and Systems - UsefulFeedback
Latest Product Updates and Feature Enhancements on UsefulFeedback
Civica Rx's low-cost insulin, biosimilar launch in US - Becker's Hospital Review
Civica Rx has launched a low-cost insulin and biosimilar product in the US, aiming to improve accessibility and affordability for patients. This initiative is part of Civica's broader strategy to add...ress high drug prices and enhance healthcare outcomes.
Civica to launch affordable long-acting insulin in pre-filled pens in 2026
Civica plans to launch insulin glargine-yfgn in pre-filled pens at a low price in January 2026, partnering with Biocon Biologics for manufacturing. The insulin will be available in the U.S. at $45 pe...r box, aiming to offer a transparent price without hidden costs. This initiative aligns with Civica's mission to provide affordable healthcare solutions.
CivicaScript Launches Treatment for Symptomatic Neurogenic Orthostatic Hypotension to Drive Savings for Patients , Healthcare System
CivicaScript has launched a new treatment for symptomatic neurogenic orthostatic hypotension, aiming to reduce costs for patients and the healthcare system.
Strategic Partnerships and Integrations of UsefulFeedback
Virginia : Partnership for Petersburg marks successes
Civica has partnered with the state of Virginia in a public-private initiative to produce affordable insulin, with a $3 million grant supporting this effort. The partnership aims to offer insulin at ...a maximum of $30 per vial or $55 for a box of five pens, significantly reducing costs for patients.
Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer
Civica has appointed Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer, effective July 21. Sehgal will lead Civicas manufacturing strategy and operations, focusing on expanding acce...ss to essential medicines. With nearly 30 years of pharmaceutical industry experience, Sehgal will oversee the Petersburg facility, which is set to produce generic sterile injectable medicines by 2026.
